Navigation Links
NORD Sponsors Rare Disease Summit
Date:5/14/2009

WASHINGTON, May 14 /PRNewswire-USNewswire/ -- A shortage of new pharmaceutical products in the pipeline combined with new scientific tools has created a climate of opportunity for the rare disease community, a senior Food and Drug Administration (FDA) official said today at a conference hosted by the National Organization for Rare Disorders (NORD).

The blockbuster model is no longer viable, said Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at FDA. As a result, she said, companies are more willing to consider new options, including more products for rare diseases.

Former National Human Genome Research Institute Director Francis Collins, MD, PhD, agreed, adding that it's time to de-risk orphan drug development, making it a more viable business model for companies.

Collins and Woodcock were among several speakers at a Partners in Progress Summit hosted by NORD in Washington, DC. NORD represents the nearly 30 million Americans who have rare diseases, or ones affecting fewer than 200,000 people.

Peter L. Saltonstall, NORD's president and CEO, noted that most rare diseases have no FDA-approved treatment and many patients are denied insurance for unapproved treatments. NORD sponsored the summit, he said, to develop a policy agenda for action to spur development of new therapies and ensure that patients have access to them.

Former FDA Commissioner David Kessler, MD, moderated the event. Speakers included thought leaders in government and industry working with rare diseases and orphan products. A theme articulated by several speakers was that now is the time for rare disease patients and researchers to press their case.

The healthcare system we know today is going to be completely transformed over the next 12 months, said Tommy Thompson, former governor of Wisconsin and former Secretary of Health and Human Services. Now is the time for action.

NORD Board of Directors Vice Chairman Frank Sasinowski announced the formation of a Rare Disease Congressional Caucus to seek creative solutions to problems faced by patients and to serve as a forum for discussion of issues related to access, research, and increased innovation.

The Caucus will also seek to increase funding for two government agencies the National Institutes of Health Office of Rare Diseases Research and the FDA Office of Orphan Products Development. In addition, it will address regulatory issues facing the pharmaceutical, biotechnology, and medical device industries, Sasinowski said.

Social Security Commissioner Michael Astrue described efforts to expedite the process of applying for Social Security disability assistance for people with severely disabling rare diseases. Under Commissioner Astrue, the Social Security Administration last fall launched a new Compassionate Allowances initiative to reduce problems encountered by people with certain severe diseases when they apply for assistance.

Presentations from the Partners in Progress Summit will be posted soon on the NORD website at www.rarediseases.org.


'/>"/>
SOURCE National Organization for Rare Disorders (NORD)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York
2. HealthCentral.com Collaborates With BreastCancer.org, Providing Quality Awareness Sponsorships to #1 Breast Cancer Resource Online
3. Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act 2009 Increases to 27 Members
4. Celebrate the Beauty of Motherhood - American Laser Centers Sponsors RoleMommy.com Mothers Day Spa Retreat & Style Lounge
5. Cosmetic Bootcamp Announces Sold Out Sponsorship for Upcoming Meeting
6. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
7. Cardinal Rigali Praises House Re-Introduction of Pregnant Women Support Act, Urges Co-Sponsorship
8. Prime Sponsors at 2009 American Heart Walk
9. Paying it Forward: Washington, DC LASIK Vision Care Practice Sponsors New Contest to Reward Good Deeds
10. American Laser Centers Sponsors SELF Magazines Workout in the Park
11. Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... All-Star Insurance, ... residential and business clients throughout eastern Texas, is announcing the launch of a new ... Recent breast cancer statistics in the United States reveal that an estimated 252, 710 ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... the Houston area with access to asset protection and financial planning services, is ... aimed at improving the lives of children with cancer and other chronic diseases. ...
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is proud to ... for 2017. Each year, research and information firm, Castle Connolly, releases their list of ... 2015, this marks the 3rd time that Dr. Canales has been recognized ...
(Date:6/22/2017)... ... , ... Groove Ring is excited to announce they've partnered with Olympic runner ... and all-purpose rings. Whether you’re an athlete, adventurer, professional, or love to venture the ... From the rock face to the auto shop, Groove Ring is the world's first ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: